About Us
From 20 years of scientific observations of metabolic change as a result of salt intake, came the discovery by Dr Karen Duggan in 2003 that a naturally occurring molecule in the human body was capable of reversing fibrosis caused by hypertension and other chronic diseases such as diabetes. In 2005 Vectus Biosystems Limited was formed to take Dr Duggan’s discovery through to an orally deliverable drug.
Today, Vectus is focused on advancing its lead compound VB0004 for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive and often fatal lung disease with significant unmet medical need. VB0004 is a first-in-class antifibrotic candidate that has demonstrated the ability to reverse established fibrosis in preclinical models and has successfully completed Phase 1a clinical studies, establishing a favourable safety and pharmacokinetic profile.